Ascendis Pharma A/S announced new data from Week 156 of its Phase 3 PaTHway Trial, confirming that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. The results were presented at ENDO 2025, the annual meeting of the Endocrine Society.
At Week 156, 88% of patients maintained normal albumin-adjusted serum calcium levels, and 96% were independent from conventional therapy, defined as taking less than 600 mg/day of calcium and no active vitamin D. The trial demonstrated sustained improvements in kidney function, with mean eGFR increasing by 8.76 mL/min/1.73 m2 across all participants.
Patients in the trial also reported continued improvements from baseline in their hypoparathyroidism-related symptoms and health-related quality of life, alongside normalization of 24-hour urine calcium excretion. TransCon PTH treatment was generally well-tolerated, with no new safety signals identified and most treatment-emergent adverse events being mild or moderate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.